0.05Open0.05Pre Close0 Volume40 Open Interest5.50Strike Price0.00Turnover262.60%IV213.56%PremiumSep 20, 2024Expiry Date0.00Intrinsic Value100Multiplier26DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.1080Delta0.1477Gamma35.40Leverage Ratio-0.0043Theta0.0001Rho3.82Eff Leverage0.0009Vega
Esperion Therapeutics Stock Discussion
Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update
Positive
Total revenue increased 186% year-over-year to $73.8 million
U.S. net product revenue grew 39% to $28.3 million
Monetized European royalties for $304.7 million, enhancing financial flexibility
Expanded payer coverage, with over 80% updating utilization management criteria
Increased preferred commercial coverage to 92% and Medicare preferred coverage to over 50%
Rec...
Hurry Up!Go ahead!🚀🚀🚀🏆🏆🏆
waiting for 12/8,good price!
every time 2-3,improve very quickly!
Will be a very good one!
New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries
Esperion (NASDAQ: ESPR) has launched a new digital marketing campaign called 'Lipid Lurkers' to educate patients about the risks of uncontrolled LDL cholesterol. The campaign uses animated characters to visually represent the unseen risk lurking in patients' artery walls. This initiative follows the recent FDA-app...
Esperion, a well-known entity in the biopharmaceutical industry trading under the Nasdaq symbol ESPR, has recently entered into a pivotal financial transaction with OMERS Life Sciences, a prominent investor in the life sciences sector. The essence of this transaction r...
No comment yet